Kitz Robert, Leung Olivia, Royer Michael
Department of Pathology and Laboratory Services, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
F. Edward Hebert School of Medicine, Uniformed Services University, Bethesda, Maryland, USA.
J Cutan Pathol. 2023 Feb;50(2):113-117. doi: 10.1111/cup.14324. Epub 2022 Sep 19.
Glomus tumors are rare mesenchymal neoplasms composed of cells resembling the glomus body. They are most frequently seen in subungual regions but have been reported to arise in almost every anatomic location. Malignant glomus tumors, also called glomangiosarcomas, of cutaneous origin are exceedingly rare with only 47 reported cases. The genetic alterations that lead to the development of cutaneous malignant glomus tumors are not well understood. Small studies report glomus tumors with mutations in glomulin (GLMN), NF1, BRAF, NOTCH, PDGFRB, KRAS, and SMARCB1. These mutations have mostly been studied in deep or visceral glomus tumors. We report a case of a cutaneous malignant glomus tumor with a CCND3 point mutation identified on next generation sequencing, without any of the previously described genetic mutations. CCND3 mutations that cause cyclin D3 amplification may prove to be targets for CDK4/6 inhibitors in the treatment of malignant glomus tumors.
血管球瘤是一种罕见的间叶组织肿瘤,由类似于血管球的细胞组成。它们最常见于甲下区域,但据报道几乎可发生于每个解剖部位。皮肤来源的恶性血管球瘤,也称为血管球肉瘤,极为罕见,仅有47例报道。导致皮肤恶性血管球瘤发生的基因改变尚不清楚。小型研究报道了血管球瘤中存在glomulin(GLMN)、NF1、BRAF、NOTCH、PDGFRB、KRAS和SMARCB1的突变。这些突变大多在深部或内脏血管球瘤中进行了研究。我们报告了一例经二代测序鉴定存在CCND3点突变的皮肤恶性血管球瘤,未发现任何先前描述的基因突变。导致细胞周期蛋白D3扩增的CCND3突变可能成为CDK4/6抑制剂治疗恶性血管球瘤的靶点。